In ER + breast cancer, the interplay between PI3K-Akt-mTOR pathway and estrogen receptor α pathway drives resistance to endocrine therapy (Cassinelli et al. 2013), suggesting that combination therapy with tamoxifen and empagliflozin could prevent or overcome resistance to anti-hormonal therapy. Here, AKT1 is linked to breast cancer.